Ascletis Pharma Past Earnings Performance
Past criteria checks 0/6
Ascletis Pharma's earnings have been declining at an average annual rate of -14.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 27.4% per year.
Key information
-14.7%
Earnings growth rate
-14.1%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | -27.4% |
| Return on equity | -11.9% |
| Net Margin | -2,561.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?
Oct 07
We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate
Dec 19We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Aug 23What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today
Nov 03Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth
Oct 13Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates
Aug 24Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation
May 19Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts
Mar 27We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely
Feb 08Revenue & Expenses Breakdown
How Ascletis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 10 | -258 | 131 | 257 |
| 31 Mar 24 | 33 | -202 | 123 | 237 |
| 31 Dec 23 | 57 | -145 | 116 | 217 |
| 30 Sep 23 | 59 | -194 | 83 | 229 |
| 30 Jun 23 | 62 | -243 | 50 | 241 |
| 31 Mar 23 | 58 | -279 | 51 | 254 |
| 31 Dec 22 | 54 | -315 | 52 | 267 |
| 30 Sep 22 | 66 | -246 | 50 | 263 |
| 30 Jun 22 | 79 | -176 | 48 | 258 |
| 31 Mar 22 | 78 | -188 | 49 | 236 |
| 31 Dec 21 | 77 | -199 | 51 | 213 |
| 30 Sep 21 | 58 | -234 | 56 | 172 |
| 30 Jun 21 | 40 | -269 | 60 | 131 |
| 31 Mar 21 | 37 | -239 | 65 | 120 |
| 31 Dec 20 | 35 | -209 | 69 | 109 |
| 30 Sep 20 | 82 | -155 | 93 | 111 |
| 30 Jun 20 | 130 | -100 | 117 | 114 |
| 31 Mar 20 | 152 | -98 | 133 | 120 |
| 31 Dec 19 | 173 | -96 | 149 | 126 |
| 30 Sep 19 | 150 | -92 | 158 | 137 |
| 30 Jun 19 | 127 | -89 | 167 | 148 |
| 31 Mar 19 | 153 | -43 | 165 | 153 |
| 31 Dec 18 | 166 | -7 | 144 | 143 |
| 30 Sep 18 | 154 | -5 | 110 | 139 |
| 30 Jun 18 | 142 | -2 | 76 | 134 |
| 31 Mar 18 | 91 | -40 | 50 | 127 |
| 31 Dec 17 | 53 | -54 | 37 | 114 |
| 31 Dec 16 | 33 | -27 | 15 | 63 |
Quality Earnings: 1672 is currently unprofitable.
Growing Profit Margin: 1672 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1672 is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Accelerating Growth: Unable to compare 1672's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1672 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 1672 has a negative Return on Equity (-11.86%), as it is currently unprofitable.